MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA WITH 10% TO 19% BLASTS
Clinical trials for MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA WITH 10% TO 19% BLASTS explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA WITH 10% TO 19% BLASTS trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA WITH 10% TO 19% BLASTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug HC-7366 tested for tough leukemia
Disease control Recruiting nowThis early-phase trial is testing a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The main goal is to find a safe dose and check for side effects. Researchers hope this drug may offer a new option f…
Matched conditions: MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA WITH 10% TO 19% BLASTS
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Donor immune cells join fight against Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial tests whether adding natural killer (NK) cells from a healthy donor to the standard drugs azacitidine and venetoclax can help control acute myeloid leukemia (AML). About 32 adults with relapsed or hard-to-treat AML will receive the combination. The main goa…
Matched conditions: MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA WITH 10% TO 19% BLASTS
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC